Are you looking to develop an antibody, ADC, AOC, RDC or Bispecific? Schedule a meeting with our scientific & commercial leadership to discuss your complex biologic or bioconjugate program during DCAT Week, March 23-26, to discover how we can de-risk and expedite your program!

Abzena has two meeting room suites at the Lotte Palace Hotel #1516 & #1517.  Our team would appreciate the opportunity to schedule time to discuss your project-specific needs and provide an update on our expanded global capabilities. Our newly enhanced cell line development platform, AbZelectPRO™ ,  can take you from DNA to RCB in just 10 weeks with 10g/L in high-performing, stable titers. It’s fully portable, with no exit fees and no royalties, and can be used for fast, stable pools for tox batches or for fully integrated GMP biologics manufacturing campaigns for the clinic.

If you are ready to achieve more from your cell line and reach IND faster, discover AbZelectPRO™ at DCAT Week.

From antibodies (mAbs) to recombinant vaccines and bioconjugates, including Antibody-Drug Conjugates (ADCs) and Antibody-Oligonucleotide Conjugates (AOCs), our team appreciates the opportunity to share how Abzena can help accelerate your program toward its next milestone.

Abzena attendees include:
– CEO, Geoff Glass
– CSO, Dr Campbell Bunce
– CCO, Joe Principe
– COO, Sean O’Brien
– SVP, Global Head of Quality, Troy Wright
– SVP, Scientific Leader, Dr Petra Dieterich
– SVP, Commercial Strategy, Gavin Murdoch
– Head of Business Development North America, Barbara Arnold
– Head of Business Development EU & Asia, Jonathan Cruickshank
– SVP, Global Marketing, Kimberly Burrell

Educational Session Sponsor on Tuesday from 9-10am : Manufacturing Investments, Capacity & Financial Outlook: A Pharma & CDMO View

The wave of announced pharmaceutical manufacturing investments in the United States has garnered the headlines, but are geographic capacity shifts really in the making? The latest analysis on capacity additions from bio/pharma companies and CDMOs. Plus: a CDMO financial outlook on the current performance and outlook for the pharmaceutical outsourcing sector. Click here for more details.

Speakers
-Sean P. McKee, Partner, PharmaBioSource
-Daniel Cohen, Managing Director and Global Head of Pharma Outsourcing Investment Banking, Morgan Stanley

Educational Session Sponsor on Tuesday from 11-12pm : Future-Proofing the Pharma Customer–Supplier Relationship

Navigating evolving tariff/trade policy and other geopolitical risks has been a challenge for bio/pharmaceutical companies and their suppliers, but what can companies do to best respond to further change—both seen and unseen? An executive panel will share first-hand experience, lessons learned, best practices and other modifications for supply assurance. Click here for more details.

Panelists
-Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer
-Emad Abdelsadek, Vice President, Sales, EMEA, BD Biopharma Systems
-Two Additional Panelists TBA
-Panel Moderator: Vishal Bhandari, Partner, Healthcare & Life Sciences Practice, Americas, Kearney

We look forward to connecting with you at DCAT 2026. Please use the form below to schedule a meeting with our team.